

PHONE 1.800.411.4363 FAX 1.800.434.9850

CONNECT





TUMOR ANALYSIS REQUISITION

PATIENT INFORMATION (COMPLETE O	NE FORM FOR FACH PERSON TESTEI	וח		
TATIENT IN ORMATION (COM ELTE OF	NETOKATOK EACHTERSON TESTEL			
Patient Last Name	Patient First Name		MI	Date of Birth (MM / DD / YYYY)
Address		City	State	ZIP Code
Division			Patient dischar	
Phone	Accession #	Hospital / Medical Record #	the hospital/fa	cility: Yes No
Biological Sex: Female	Male Unknown Gend	der identity (if different from left):		
REPORTING RECIPIENTS				
Ordering Physician		Institution Name		
o. doi.ing . injuician				
Email (Required for International Clients)		Phone	Fax	
ADDITIONAL RECIPIENTS			•••••	
Name		Email	Fax	
Name		Email	Fax	
PAYMENT (FILL OUT ONE OF THE OPTI	IONS BELOW)			
SELF PAYMENT				
Pay With Sample Bill	To Patient			
O INSTITUTIONAL BILLING				•••••••••••••••••••••••••••••••••••••••
Institution Name	Institution Code In	stitution Contact Name Inst	itution Phone	Institution Contact Email
O INSURANCE				
Do Not Perform Test Until Patier	nt is Aware of Out-Of-Pocket Costs			
REQUIRED ITEMS 1. Copy of the	Front/Back of Insurance Card(s) 2. ICD10	Diagnosis Code(s) 3. Name of Ordering P	Physician 4. Insured	Signature of Authorization
	/ /	:		/ /
Name of Insured	Insured Date of Birth (MM / DD / YYYY	Y) Name of Insured	Ins	sured Date of Birth (MM / DD / YYYY)
Patient's Relationship to Insured	Phone of Insured	Patient's Relationship to In:	sured Ph	one of Insured
Address of Insured		Address of Insured		
City	State ZIP	City	Sta	ate ZIP
Primary Insurance Co. Name	Primary Insurance Co. Phone	Secondary Insurance Co. N	ame Se	condary Insurance Co. Phone
				,
Primary Member Policy #	Primary Member Group #	Secondary Member Policy	# Se	condary Member Group #
By signing below, I hereby authorize Baylor Ger for any co-pay, co-insurance, and unmet deduct authorized services. I understand that I am resp does not cover routine screening tests.	ible that the insurance policy dictates, as well	as any amounts not paid by my insurance car	rier for reasons includin	g, but not limited to, non-covered and non-
Datient / Cuardian Dainted Menne	Berten	/ Cuardian Cinnatura		//
Patient / Guardian Printed Name STATEMENT OF MEDICAL NECESSITY		Guardian Signature		Date (MM / DD / TTTT)
This test is medically necessary for the risk asse and treatment decisions. The person listed as the have consented to genetic testing.	ssment, diagnosis, or detection of a disease, ill			
				///
Physician's Printed Name	Physicia	n's Signature		Date (MM / DD / YYYY)



PHONE 1.800.411.4363 FAX 1.800.434.9850

CONNECT







TUMOR ANALYSIS REQUISITION

				///		
Patient Last Name	Patient First Name		MI	Date of Birth (MM / DD / YY	YY)	Biological Sex
ETHNICITY						
African American	Hispanic American		Pac	ific Islander (Philippines, Micron	esia, Mal	aysia, Indonesia)
Ashkenazi Jewish	Mennonite		◯ Sou	th Asian (India, Pakistan)		
East Asian (China, Japan, Korea)	Middle Eastern (Saudi Arabia, Qatar, Iraq, T	urkey)	◯ Sou	theast Asian (Vietnam, Cambo	dia, Thai	iland)
Finnish	Native American		Southern European Caucasian (Spain, Italy, Greece)			
French Canadian	Northern European Caucasian (Scandinavia	an, UK, Germany)	Other (Specify):			
SAMPLE INFORMATION						
Date of Collection (MM / DD / YYYY)	Time of Collection		A-certified l	nly be accepted if the isolation of aboratory or a laboratory meetin he CMS.		
REQUIRED FOR BREAST CANCER FF	PE SAMPLES ······					
Method of Fixation	Time to Tissue Fixation	Tissue Fixatio	n Time			
SAMPLE TYPE (PLEASE REFER TO PAGE 5	FOR SAMPLE REQUIREMENTS)					
Blood in EDTA Tube (Purple-Top) +	FFPE - Slides * #:		\circ	DNA (Concentration) + ±*:		
Blood in Sodium Heparin (Green-Top)	+ FFPE - Tissue Block *		\circ	RNA (Concentration) + **:		
Bone Marrow in Sodium Heparin (Gre	en-Top) + Fresh Frozen Tissue ±*		\circ	Other **:		
Bone Marrow in EDTA (Purple-Top) +	Tissue in Medium **					
molecular testing, and pathology reports). Co		available.	Biolo	ogical Sex of Bone Marrow splant Donor (select one):	○ Fe	emale () Male
INDICATION FOR TESTING (REQUIRED)						
		10040 0:	()			
Indication(s)		ICD10 Diagnosis Cod	e(s)			
RETURN OF FFPE SPECIMENS		SPECIMEN RETRIE	VAL			
address information below, or affix pr		☐ I want Baylor Ge	enetics to r	request the specimen. (Comple	ete inforr	nation below)
This section will be used as the return address la	odel.					
Institution	ATTN	Location of Specime	n			
Address		Contact Name				
City	State ZIP	Phone #		Fax #		

PHONE 1.800.411.4363 FAX 1.800.434.9850

CONNECT







TUMOR ANALYSIS REQUISITION

_								//	
	Patient Last N			nt First Name		DI I	MI		ological Sex
	M = Blood in S M = Tissue in N		= Bone Marrow in Soc = Slides/Block	lium Heparin (green-top)			in EDTA (purple-top) les/Block	BME = Bone Marrow in EDTA (pur T = Fresh Frozen Tissue	pte-top)
1	CANCER MO	LECULAR ANALYSIS			CY	TOGEN	NETIC TESTS		
-	SINGLE GENE	TESTING			SII	NGLE F	ISH PROBES ·····		
	TEST CODE	TEST NAME		SAMPLE TYPE		ST CODE			SAMPLE TYPE
ī	9202	B-Cell Clonality Screening (IgH and IgK) b	ov PCR	BE, BME, FFPE, T		8030	ALK Rearranger	nent	FFPE
Ť	7202	BCR-ABL1, Major (p210), Quantitative	,	BE, BME		8725	AML1/ET0: t(8;2	1) [AML]	ВН, ВМН
F	8972	BCR-ABL1, Minor (p190), Quantitative		BE, BME		8785	BCL2 Rearrange	ment	FFPE
_		BCR-ABL1, Qualitative Analysis w/ Reflex				8775	BCL6 Rearrange	ment	BH, BMH, FFPE
L	9070	to BCR-ABL1 Quantitative 4		BE, BME		8750	BCR/ABL: t(9;22) [CML/ALL/AML]	ВН, ВМН
	9305	BCR-ABL1 Mutation Analysis for Tyrosine Inhibitor Resistance by NGS	e Kinase	BE, BME	H	8740 8730	CBFB: inv(16) [A	ML] q [Hypereosinophilic Syndrome]	BH, BMH BH, BMH
	9003	BRAF V600 Mutation Analysis		BE, BME, FFPE	F	8710	Deletion 5: [MDS		BH, BMH
	9016	CALR (Calreticulin) Exon 9 Mutation Analy	ysis by PCR	BE, BME	T	8715	Deletion 7: [MDS		BH, BMH
	9086	CEBPA Mutation Detection		BE, BME		8720	Deletion 20q12:	[MDS]	ВН, ВМН
	9030	EGFR Mutation Detection by Pyrosequence	cing	FFPE		8065	DXZ1/DYZ3		ВН, ВМН
Ī	9045	FLT3 Mutation Detection by PCR ²		BE, BME		8035	EGFR		FFPE
Ī	9104	Gastrointestinal Stromal Tumor Mutation	(KIT, PDGFRA)	FFPE		8385	Gain Chromosor	ne 8	ВН, ВМН
Ī	9060	IGHV Mutation Analysis by Sequencing		BE, BME		8780	IGH Rearrangen	nent	ВН, ВМН
Ī	9015	JAK2 Exon 12 Mutation Analysis by PCR		BE, BME	L	8770	IGH/CCND1: t(11	;14) [Mantle Cell Lymphoma]	BH, BMH, FFPE
ī	9010	JAK2 Gene, V617F Mutation, Qualitative		BE, BME	Ļ	8795	IGH/MYC Analys		FFPE
Ť	8970	KIT (D816V) Mutation by PCR		BE, BME	늗	8786	MALT1 Lymphor		BH, BMH
Ť	9103	KIT Mutations, Melanoma (including PDGI	FRA)	FFPE	누	8705	MECOM (EVI1) A	<u> </u>	BH, BMH FFPE
		KIT Mutations in AML by Fragment Analys			늗	8095 8745	MET Amplification	on	BH, BMH
L	9105	and Sequencing		BE, BME	늗	8760	MYC translocation	nn	BH, BMH, FFPE
	9128	KRAS Mutation Detection		FFPE	H	8788	p53	<u> </u>	BH, BMH
	8974	MGMT Methylation Detection by PCR		FFPE	F	8735	PML/RARA: t(15	;17) [AML]	BH, BMH
	9150	Microsatellite Instability (MSI), HNPCC/Ly Syndrome, by PCR ³	nch	FFPE		8031	RET Rearranger	nent	FFPE
_		MPL Codon 515 Mutation Detection by				8781	ROS1 Rearrange	ement	FFPE
_	9020	Pyrosequencing, Quantitative		BE, BME		8075	SS18 [Synovial :	Sarcoma]	FFPE
_[8973	MYD88 L265P Mutation Detection by PCR	R, Quantitative	BE, BME, FFPE		8080	TCF3/PBX1 [ALL	.]	ВН, ВМН
	9005	NPM1 Mutation Detection by RT-PCR, Qua	antitative	BE, BME		8755	TEL/AML1: t(12;	21) [ALL]	ВН, ВМН
	8971	NRAS Mutation Detection by Pyrosequence	cing	FFPE		8400	OTHER, Probe N	ame:	
	8976	PD-L1 28-8 pharmDx by Immunohistoche Interpretation, nivolumab (OPDIVO)	emistry with	FFPE	CL	ASSICA	L CHROMOSOME ANA	LYSIS ·····	
Г	8975	PD-L1 22C3 IHC for NSCLC by Immunohis		FFPE	TE	ST CODE	TEST NAME		SAMPLE TYPE
_		with Interpretation, pembrolizumab (KEY PD-L1 22C3 IHC with Combined Positive 9			Ļ	8300	Hematologic Ca	ncer	ВН, ВМН
L	8977	Interpretation, pembrolizumab (KEYTRUE	DA)	FFPE		8050	Solid Tumor		TM
	9080	PML-RARA Translocation, t(15;17) by RT- Quantitative	PCR,	BE, BME	FIS	SH PAN	ELS		• • • • • • • • • • • • • • • • • • • •
	9217	T-Cell Clonality Screening by PCR		BE, BME, FFPE, T	TES	T CODE	TEST NAME		SAMPLE TYPE
	9055	TP53 Somatic Mutation, Prognostic		BE, BME, FFPE		8789	<u> </u>	nphoma (MYC translocation, BCL2 rearrangement, BCL6 rearrangemen	t) FFPE
						8010	Trisomy 10) If the result is negative, refi	ene fusion, KMT2A rearrangement, IGH rearrangement, Trisomy 4, ex to 8012	вн, вмн
F	REFLEX TEST	s		• • • • • • • • • • • • • • • • • • • •		8012		BCR/ABL1-ASS1, JAK2, EPOR, CRLF2)	ВН, ВМН
L	Reflex Request	(Please describe below):			$\overline{\Box}$	8792		ion, KMT2A rearrangement, ETV6/RUNX1 translocation, Trisomy 4,	BM, BMH
					一一	8000	Trisomy 10, TCF3/PBX1 amplificati AMI (Trisomy 8, AMI /FT0, MI rear	rangement, PML/RARA, CBFB inversion)	BH, BMH
					H			AYB del, 13g del, IGH rearrangement, IGH/CCND1 fusion)	BH, BMH
					+	8791	Eosinophilia (PDGFRB rearrangeme	nt, FGFR1 rearrangement, JAK2 rearrangement, PDGFRA/CHIC2/FIP1L1	BH, BMH
					∺		rearrangement, CBFB rearrangement MDS (5 del, 7 del, Trisomy 8, MLL r		BH. BMH
					<u> </u>	0000		earrangement, zuq det) del, IGH rearrangement, Trisomy 15, p53 del, Trisomy 7, CKS1B/CDKN2I	
						8015	amplification/deletion) If IGH rearrangement positi		ВН, ВМН
L						8790		ent (IGH/MAF fusion, IGH/FGFR3 fusion, IGH/CCND1 fusion)	ВН, ВМН
		5: If sending FFPE slides, 20 slides are required for 5: Test will be sent to LabPMM for analysis and re				8020	NHL (BCL6 rearrangement, IGH/CC BCL2 rearrangement)	ND1 fusion, MYC rearrangement, MALT1 rearrangement,	ВН, ВМН
		0: Please submit BOTH a source of tumor tissue (F		a source of normal tissue		8787		LK rearrangement, MET amplification, RET rearrangement,	FFPE
4		0: If BCR-ABL1, Major (p210) is detected, reflex to	9065, and if BCR-ABL1,	Minor (p190) is detected,	一一	8793		K2 rearrangement, NTRK3 rearrangement)	FFPE
							-		



PHONE 1.800.411.4363 FAX 1.800.434.9850









TUMOR ANALYSIS REQUISITION

SAMPLE SPECIFICATIONS TABLE

FOR CLIENT INFORMATION ONLY. Not required with sample submission.

		RECOMMENDED AMOUNT			
ABBREVIATION	SAMPLE NAME	(2 YRS - ADULT)	(NEWBORN - 2YRS)	SHIPPING INSTRUCTIONS	SPECIAL NOTES
BE	Blood in EDTA tube (purple-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laborator reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available
ВН	Blood in Sodium Heparin tube (green-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laborator reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available
ВМЕ	Bone Marrow in EDTA tube (purple-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laborator reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available
ВМН	Bone Marrow in Sodium Heparin tube (green-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laborator reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available
DNA	DNA, Extracted	At Least 100 ng	At Least 100 ng	Ship at room or refrigerated temperature in an insulated container by overnight courier. May also be shipped frozen on minimum of 10 lbs of dry ice in an insulated container by overnight courier.	Minimum concentration of 25ng/uL. Attach clinical notes, concurrent laboratory reports, and/or surgical pathology report, as applicable. Please send a corresponding representative H+E slide, if available.
FFPE	FFPE - Block	See Special Notes	See Special Notes	Ship at room temperature in an insulated container by overnight courier. If shipping during the summer months please include a cold-pack to avoid extreme temperatures. Do not heat or freeze.	Paraffin-embedded, formalin-fixed tissue block containing ≥20% tumor nuclei with a minimum tumor surface area of 5mm x 5mm (25mm²). Decalcified specimens are not accepted. Surgical pathology report must be attached for all tissue samples.
FFPE	FFPE - Slides	See Special Notes	See Special Notes	Ship at room temperature in an insulated container by overnight courier. If shipping during the summer months please include a cold-pack to avoid extreme temperatures. Do not heat or freeze.	10 - 15 unstained 5µm FFPE slides containing ≥20% tumor nuclei with a minimum tumor surface area of 5mm x 5mm (25mm²). For smaller specimens, 20 or more unstained 5µr FFPE slides containing ≥20% tumor nuclei should be submitted. Decalcified specimens are not accepted. Surgical pathology report must be attached for all tissue samples.
					For test codes 9505: 20 slides are required for submission.
RNA	RNA, Extracted	At Least 100 ng	At Least 100 ng	Ship frozen on minimum of 10 lbs of dry ice in an insulated container by overnight courier.	Minimum concentration of 25ng/uL. Attach clinical notes, concurrent laboratory reports, and/or surgical pathology report, as applicable. Please send a corresponding representative H+E slide, if available.
SA	Saliva	See Special Notes	See Special Notes	Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	Collected with Oragene DNA Self-Collection Kit (provided by Baylor Genetics with instructions).
Т	Fresh Frozen Tissue	150 mg	150 mg	Ship frozen on minimum of 10 lbs of dry ice in an insulated container by overnight courier.	Fresh tissue snap frozen at ≤-20°C. Store at ≤-20°C. Surgical pathology report must be attached for all tissue samples. Surgical pathology report may be sent later as soon as it becomes available. Please send a corresponding representative H+E slide, if available.
ТМ	Fresh Tissue in Medium	0.5 - 1 cm³ or more	0.5 - 1 cm³ or more	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 48 hours of collection.	Transport tumor tissue in a sterile, screw-top container filled with tissue culture transport medium. If tissue culture transport medium is not available, collect in plain RPMI, Hanks solution, or saline. Surgical pathology report must be attached for all tissue samples. Surgical pathology report may be sent later as soon as it becomes available. Please send a corresponding representative H+E slide, if available.



PHONE 1.800.411.4363 FAX 1.800.434.9850 CONNECT





INFORMED CONSENT FOR TUMOR ANALYSIS TESTING

Patient Last Name	Patient First Name	MI	Date of Birth (MM / DD / YYYY)	Biological Sex

INFORMED CONSENT FOR GENETIC TESTING

TEST INFORMATION

This consent form will provide you with information regarding genetic testing, which you should discuss with your healthcare provider or a genetic counselor. In order to ensure that you have understood the purpose and significance of genetic testing, we have provided information about the testing process and potential results below.

The purpose of genetic testing is to identify the cause of a suspected disease in you or your family. The testing analyzes your genetic material (DNA) for an abnormal change (variant) that could explain the disease you or members of your family are experiencing. Genetic testing can be a diagnostic test, which is used to identify or rule out a specific genetic condition. Genetic screening tests are used to assess the chance for a person to develop or have a child with a genetic condition. Genetic screening tests are not typically diagnostic, and results may require additional testing.

The purpose of this test is to see if you or your child may have a genetic variant or chromosome rearrangement. This may cause a genetic disorder or may determine the chance that you or your child will develop or pass on a genetic disorder in the future. "Your child" can also mean your unborn child, for the purposes of this consent.

In a genetic test, depending on the case, you can be tested for:

- A single gene/variant responsible for a specific, suspected genetic disease.
- Multiple genes in parallel.

The sample/specimen that is needed to perform the genetic test is stated in the test order form and is typically blood or purified DNA, but may also be tissue, saliva or buccal swab.

RESULTS

There are several categories of test results that may be reported including:

- **Positive:** Positive or "abnormal" results mean there is a change in the genetic material found that is related to your/your child's medical issues or that you/your child are at an increased risk of developing the disorder in the future. It is possible to test positive for more than one genetic variant.
- Negative: Negative or "normal" results mean no relevant genetic change related to your/your child's medical issues was detected. This does not mean there is no genetic change, but it may mean that the type of testing performed could not detect it.
- Results of Unclear Significance: Testing can detect change(s) in DNA which we do not yet fully understand. These alterations are also referred to as variants of uncertain significance (VUS). Additional studies may be recommended if a VUS is identified in a gene that may be associated with your/your child's medical concerns.
- Secondary / Incidental Findings: Testing can sometimes detect a change in a person's DNA unrelated to the reason for testing. If this change has medical or reproductive significance, it is called a secondary or incidental finding.

CONSIDERATIONS AND LIMITATIONS

- Results may indicate affected status, increased risk to someday be affected with, and/or reproductive risk for a genetic disorder. It is important to understand that genetic tests, even if negative, are not exhaustive. It is not possible to exclude risks for all possible genetic diseases for yourself and your family members.
- A positive test result is an indication that the individual(s) being tested may be predisposed to or have the specific disease or condition which prompted
 testing. You might consider additional independent testing, consult a personal physician, or pursue genetic counseling.
- It is possible that the knowledge of the test results may result in psychological stress for you and your family. It is always recommended to discuss the results with your healthcare provider or genetic counselor.
- If several family members are tested, the correct interpretation of the results depends on the provided relationships between family members. In rare cases, genetic testing can reveal that the true biological relationships in a family are not as they were reported. If a discrepancy is identified, it may be necessary to report this to the physician who ordered the testing.
- Genetic testing is highly accurate. Rarely, inaccurate results may occur for various reasons. These reasons include, but are not limited to, mislabeled samples, inaccurate reporting of clinical/medical information, or rare technical errors.
- If you sign this consent form, but you no longer wish to have your sample(s) tested, you can contact your physician to cancel the test. If testing is complete, but you have not received your results yet, you can inform your physician that you no longer wish to receive the results. If you withdraw consent for testing after 5pm CST the next business day following sample receipt by the laboratory, you will be charged for the full cost of the test.

PATIENT CONFIDENTIALITY AND SPECIMEN RETENTION

- Results will only be released to a licensed healthcare provider, to those allowed access to test results by law, and to those authorized in writing.
- In rare cases, persons with genetic diagnoses have experienced problems with insurance coverage and employment. The U.S. Federal Government has
 enacted several laws that prohibit discrimination based on genetic test results by health insurance companies and employers. In addition, these laws
 prohibit unauthorized disclosure of this information. For more information, you can visit www.genome.gov/10002077.
- Samples will be retained in the laboratory in accordance with the laboratory retention policy.
- After testing is complete, the de-identified submitted specimen may be used for test development and improvement, internal validation, quality
 assurance, and training purposes. DNA specimens are not returned to individuals or to referring heath care providers unless specific prior
 arrangements have been made.



PHONE 1.800.411.4363 FAX 1.800.434.9850 CONNECT





0

INFORMED CONSENT FOR TUMOR ANALYSIS TESTING

			1	/	
Patient Last Name	Patient First Name	MI	Date of Birth (MM	/ DD / YYYY)	Biological Sex
INFORMED CONSENT FOR GENETIC 1	ESTING				
PATIENT CONFIDENTIALITY AND SF	PECIMEN RETENTION (CONT.) ·····				
	York State will not be included in the de-identif after the sample was taken, unless specifically sample.				
	ndications for testing and clinical status obtaine ed in scientific publications or presentations, bu r publications/presentations.				
RESEARCH & RECONTACT CONSENT					
For more information on research appropriate box.	at Baylor Genetics, please visit baylorgenetics.	com. Please read the belo	ow statements car	efully and ch	eck the
Note: If left blank, consent is interp	preted as "NO."				
☐ I agree to use of my de-identifi	ed specimen for research to improve genetic te	sting for all patients and	contribute to scien	itific researcl	n.
	dent, and I give Baylor Genetics permission to s and possible research studies.	tore my specimen in acco	ordance to the labo	ratory retent	ion policy for
☐ In addition to agreeing above, I	agree to be contacted by Baylor Genetics regar	rding research opportunit	ties.		
PATIENT AUTHORIZATION					
explanations from my physician re	nt, I acknowledge that I have read and understa garding the purpose, scope, type and significan d the necessary time to make an informed deci	nce of the planned genetic	testing and achiev		
I give permission to Baylor Genetic	cs to conduct genetic testing as recommended b	oy my physician.			
Patient Printed Name	Patient Signature			Date (DI	D/MM/YYYY)
Patient's Legal Guardian Printed Name	Patient's Legal Gua	ardian Signature		Date (DI	D/MM/YYYY)